Surrozen

Surrozen

Surrozen was founded in 2016 by K. Christopher Garcia, Roeland Nusse, and Calvin Kuo, researchers who translated decades of Wnt-pathway biology out of Stanford into a venture-backed company. Wnt signaling controls tissue repair in the retina, liver, lung, and intestine, and the firm’s founding insight was that selective agonism could restore function in diseased organs that lack regenerative capacity. The team originally pursued broad indications including inflammatory bowel disease and hearing loss, but narrowed sharply after a Phase 1 readout. The company now concentrates on two antibody-based Wnt-modulating programs. SZN-043 targets severe alcohol-associated hepatitis, a liver condition with no approved therapies, where hepatocyte regeneration could change the standard of care. SZN-413 addresses vascular eye disease — including diabetic retinopathy and wet age-related macular degeneration — by activating Wnt signaling in retinal endothelial cells. Both programs are built on SWAP (Surrozen Wnt/Antibody Platform) molecules, which bivalently engage Frizzled receptors and LRP5/6 co-receptors to mimic natural Wnt biology. Surrozen out-licensed its lacrimal gland regeneration program to Boehringer Ingelheim in 2022, a deal that brought non-dilutive financing while the firm reset its internal pipeline. The company went public in August 2021 via a merger with Consonance-HFW Acquisition Corp., a SPAC, listing on Nasdaq under the ticker SRZN. By late 2022, workforce reductions trimmed headcount and refocused operations entirely on the two lead assets. February 2024: Surrozen completed a reverse stock split to regain Nasdaq listing compliance, closing at a ratio that consolidated its public float (per SEC filing, February 2024). The firm maintains its headquarters in South San Francisco and operates as a single-entity, capital-markets-funded biotech without a parent family-office structure. Surrozen is structurally unusual among preclinical biotechs because its platform is not a therapeutic area but a signaling pathway. Wnt biology is notoriously difficult to drug — the natural ligands are lipidated and insoluble — yet the firm’s SWAP technology produces stable, receptor-specific antibody fusions that sidestep that obstacle. That platform specificity means the company’s survival rests on demonstrating tissue-selective agonism without triggering Wnt-driven hyperplasia elsewhere, a narrow therapeutic window that remains its central scientific question.